Barclays
BHVN

Barclays’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Barclays’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20,800
Closed -$1.78M – 5434
2020
Q4 		$1.78M Buy
+20,800
New +$1.76M ﹤0.01% 2317
2020
Q1 		– Sell
-600
Closed -$33K – 6791
2019
Q4 		$33K Buy
+600
New +$29.7K ﹤0.01% 5867
2019
Q3 		– Sell
-20,000
Closed -$876K – 7541
2019
Q2 		$876K Buy
+20,000
New +$1.13M ﹤0.01% 3824
2018
Q2 		– Sell
-169,800
Closed -$4.37M – 7684
2018
Q1 		$4.37M Buy
+169,800
New +$5.08M ﹤0.01% 1742

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Barclays's BHVN Position: Q4 2022 in Review

Barclays sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 218,095 shares — an estimated $33M sold.

Barclays first reported a position in BHVN in Q2 2017 and held it in 22 quarters. The position peaked at $33M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Barclays reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Barclays sold 218,095 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $33M.
  • Barclays first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 22 quarters.
  • Barclays's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $33M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.